|Bid||2.62 x 60000|
|Ask||2.65 x 197800|
|Day's Range||2.57 - 2.62|
|52 Week Range||2.40 - 3.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 22, 2016 - Mar 28, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.92|
Transgene , a biotech company that designs and develops viral-based immunotherapies, today announces that the first patient has been treated at the Curie Institute, Paris, France, in a Phase 1b/2 clinical trial evaluating the combination of TG4001 with avelumab* as a treatment for human papillomavirus type 16 positive recurrent or metastatic cancers, such as oropharyngeal squamous cell carcinoma of ...
SEOUL, Korea and SAN FRANCISCO and HONG KONG, July 21, 2017 /PRNewswire/ -- SillaJen, Inc., (215600.KQ), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and Lee's Pharmaceutical Holdings Ltd. (0950.HK), a research based biopharmaceutical company, announced approval (Approval No. 2017L04441) by the China Food and Drug Administration (CFDA) to conduct a Phase 3 clinical trial for advanced liver cancer using its oncolytic immunotherapy called Pexa-Vec (formerly JX-594), the PHOCUS study. SillaJen and Lee's Pharmaceutical participated in a first of its kind Chinese Center for Drug Evaluation advisory committee meeting for this approval, which was held earlier this year to promote transparency in the China drug development process. At the end of the meeting, the committee voted, and it was announced by the chairman of the advisory committee, that the trial had been approved to be conducted in China.
Bristol-Myers Squibb Company and Transgene today announced a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo + standard chemotherapy as a first-line treatment for advanced non-squamous non-small cell lung cancer in patients whose tumors have low or undetectable ...
SEOUL, South Korea, SAN FRANCISCO and STRASBOURG, France, April 24, 2017 /PRNewswire/ -- SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and Transgene (TNG.PA), a French biotechnology company focused on discovering and developing immune-targeted immunotherapies for the treatment of cancer and infectious diseases, have enrolled the first European patient in the ongoing multinational randomized Phase 3 open-label study of Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC). The trial is evaluating the use of Pexa-Vec to treat HCC patients who have failed locoregional therapies and are eligible for treatment with sorafenib (Nexavar®), the only approved systemic treatment for advanced HCC.